{"title":"Helicobacter pylori: a pathogenic threat to the gastric mucosal barrier.","authors":"F S Oluwole","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Peptic ulcer disease is a multi-factorial disorder of the gastrointestinal tract with a global prevalence affecting about 4.6 million people annually and having a mortality of one death per 10,000 cases. Helicobacter pylori (H. pylori) plays a profound role in the pathogenesis of chronic gastritis, peptic ulcer, including gastric mucosa-associated lymphoid tissue and carcinoma. Any compromise to the gastric mucosal barrier will greatly affect the integrity of the stomach. H. pylori is an organism which mediates a compromise of the gastric mucosal barrier by stimulating increased gastric acid secretion, causing alteration of certain immune factors, penetration of the mucosal layer and provoking persistent inflammation even without invading the mucus membrane. All the different lines of therapy have not shown maximal efficacy in the eradication/cure of the infection in patients. Consequently, alternative therapies including phytomedicines and probiotics have been introduced both in the quest for better eradication therapies and in addressing the problem of H. pylori relapse. In the light of the increasing antibiotic resistance associated with current therapies, the use of herbal preparations or its concomitant use with current therapy has the potential to contribute additive and synergistic effect in the eradication of the H. pylori infection. This review highlights the anti-H. pylori herbal preparations tested and in current use.</p>","PeriodicalId":7616,"journal":{"name":"African journal of medicine and medical sciences","volume":"44 4","pages":"289-96"},"PeriodicalIF":0.0000,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"African journal of medicine and medical sciences","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Peptic ulcer disease is a multi-factorial disorder of the gastrointestinal tract with a global prevalence affecting about 4.6 million people annually and having a mortality of one death per 10,000 cases. Helicobacter pylori (H. pylori) plays a profound role in the pathogenesis of chronic gastritis, peptic ulcer, including gastric mucosa-associated lymphoid tissue and carcinoma. Any compromise to the gastric mucosal barrier will greatly affect the integrity of the stomach. H. pylori is an organism which mediates a compromise of the gastric mucosal barrier by stimulating increased gastric acid secretion, causing alteration of certain immune factors, penetration of the mucosal layer and provoking persistent inflammation even without invading the mucus membrane. All the different lines of therapy have not shown maximal efficacy in the eradication/cure of the infection in patients. Consequently, alternative therapies including phytomedicines and probiotics have been introduced both in the quest for better eradication therapies and in addressing the problem of H. pylori relapse. In the light of the increasing antibiotic resistance associated with current therapies, the use of herbal preparations or its concomitant use with current therapy has the potential to contribute additive and synergistic effect in the eradication of the H. pylori infection. This review highlights the anti-H. pylori herbal preparations tested and in current use.
消化性溃疡是一种多因素的胃肠道疾病,全球患病率每年影响约460万人,死亡率为每10,000例死亡1例。幽门螺杆菌(Helicobacter pylori, H. pylori)在慢性胃炎、消化性溃疡,包括胃黏膜相关淋巴组织和癌的发病机制中发挥着重要作用。任何对胃粘膜屏障的损害都会极大地影响胃的完整性。幽门螺杆菌是一种通过刺激胃酸分泌增加,导致某些免疫因子改变,渗透粘膜层,即使不侵犯粘膜也能引起持续炎症的生物。所有不同的治疗方法在根除/治愈患者感染方面并没有显示出最大的功效。因此,包括植物药物和益生菌在内的替代疗法已经被引入,以寻求更好的根除疗法和解决幽门螺杆菌复发的问题。鉴于与当前治疗相关的抗生素耐药性日益增加,使用草药制剂或与当前治疗同时使用有可能在根除幽门螺杆菌感染方面产生附加和协同效应。这篇综述强调了反h。经测试和目前使用的幽门螺杆菌草药制剂。